BusinessActinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform TechnologyBy Nasdaq OMXMar 28, 2018, 12:01 PM UTC
BusinessActinium Pharmaceuticals Announces Appointment of Jehan Rowlands, Pharm.D. as Vice-President, Head of Regulatory AffairsBy Nasdaq OMXMar 14, 2018, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Present at the BIO CEO & Investor ConferenceBy Nasdaq OMXFeb 5, 2018, 9:15 PM UTC
BusinessActinium Pharmaceuticals Announces Acceptance of Abstract for AACR Annual Meeting Highlighting Superior In Vivo Survival Data for Actinium Labelled Daratumumab Versus Unlabeled Daratumumab, A Blockbuster ProductBy Nasdaq OMXFeb 1, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Appoints Dr. Dale L. Ludwig, Ph.D. as Chief Scientific Officer to Lead Efforts Focused on the Company’s AWE Technology Platform and Research ProgramsBy Nasdaq OMXJan 8, 2018, 12:31 PM UTC
BusinessActinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-MBy Nasdaq OMXDec 11, 2017, 9:15 PM UTC
BusinessActinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual MeetingBy Nasdaq OMXDec 11, 2017, 11:30 AM UTC
BusinessActinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail RobozBy Nasdaq OMXNov 13, 2017, 12:30 PM UTC
